We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    AZI-P4-004
Previous Study | Return to List | Next Study

A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02079805
First Posted: March 6, 2014
Last Update Posted: August 2, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Takeda
  Purpose
Multicenter, randomized, open-label, parallel-group exploratory study to explore the effects of azilsartan (Azirva), compared with telmisartan, on insulin resistance in participants with essential hypertension complicated by type 2 diabetes mellitus

Condition Intervention Phase
Essential Hypertension Complicated by Type 2 Diabetes Mellitus Drug: Azilsartan Drug: Telmisartan Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R

Resource links provided by NLM:


Further study details as provided by Takeda:

Primary Outcome Measures:
  • Change in Insulin Resistance Index (HOMA-R) From Baseline at the End of the Treatment Period (Week 12) [ Time Frame: Baseline and Week 12 ]
    Change from the start of the treatment period (baseline) at the end of the treatment period (Week 12) was reported. Insulin Resistance Index (HOMA-R) measures insulin resistance, calculated by fasting insulin (μU/mL) multiplied by fasting glucose (mg/dL), and divided by a constant (405).


Secondary Outcome Measures:
  • Change in Fasting Blood Glucose From Baseline at the End of the Treatment Period (Week 12) [ Time Frame: Baseline and Week 12 ]
    Change from baseline in fasting blood glucose values collected at week 12 or final visit relative to baseline was reported.

  • Change in Fasting Insulin From Baseline at the End of the Treatment Period (Week 12) [ Time Frame: Baseline and Week 12 ]
    Change from baseline in fasting insulin values collected at week 12 or final visit relative to baseline was reported.

  • Change in Glycosylated Hemoglobin (HbA1c) From Baseline at the End of the Treatment Period (Week 12) [ Time Frame: Baseline and Week 12 ]
    Change from baseline in the values of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 or final visit relative to baseline was reported.

  • Change in Homeostasis Model Assessment of Beta Cell Function (HOMA-β) From Baseline at the End of the Treatment Period (Week 12) [ Time Frame: Baseline and Week 12 ]
    Change from baseline in HOMA-β collected at week 12 or final visit relative to baseline was reported. Homeostasis model assessment of beta cell function measures as following; HOMA-β = fasting insulin (μU/mL) ×360/{fasting glucose (mg/dL) - 63}.

  • Change in 1,5-anhydroglucitol (1,5-AG) From Baseline at the End of the Treatment Period (Week 12) [ Time Frame: Baseline and Week 12 ]
    Change from baseline in 1,5-G concentration collected at week 12 or final visit relative to baseline was reported.

  • Number of Participants With Treatment-Emergent Adverse Events [ Time Frame: Up to Week 12 ]

Enrollment: 33
Study Start Date: June 2014
Study Completion Date: April 2016
Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Azilsartan 20 mg
Participants will receive azilsartan 20 mg once daily in the morning before or after breakfast.
Drug: Azilsartan
Azilsartan tablets
Other Name: Azilva Tablets
Active Comparator: Telmisartan 40 mg
Participants will receive telmisartan 40 mg once daily in the morning before or after breakfast.
Drug: Telmisartan
Telmisartan tablets
Other Name: Micardis Tablets

Detailed Description:
The primary objective of the present study is to explore the effects of azilsartan 20 mg, compared with telmisartan 40 mg, once daily orally for 12 weeks on insulin resistance in participants with essential hypertension complicated by type 2 diabetes mellitus.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. The participant was given the diagnosis of grade I or II essential hypertension and was judged by the principal investigator or investigator that they can be appropriately treated with azilsartan 20 mg and telmisartan 40 mg.
  2. Sitting systolic blood pressure of ≥ 130 mmHg and < 180 mmHg or sitting diastolic blood pressure of ≥ 80 mmHg and < 110 mmHg at the start of the treatment period (Week 0) Sitting blood pressure will be measured until 2 consecutive stable measurements are obtained (i.e., the difference between 2 measurements: diastolic blood pressure of <5 mmHg and systolic blood pressure of < 10 mmHg) after resting in a sitting position for at least 5 minutes. The average value of the last 2 measurements will be recorded (the first the decimal place is rounded off).
  3. Type 2 diabetes mellitus
  4. HbA1c (NGSP (National Glycohemoglobin Standardization Program) value) of < 8.4% during 3 months before informed consent, with a ≤ 0.3% change in HbA1c (peak minus nadir) during 3 months before informed consent
  5. No change in diet/exercise therapy during the 3 months before the informed consent in a participant who has been on diet/exercise therapy and instructed to improve life style (e.g., diet and exercise)
  6. Age ≥ 20 years at the time of consent
  7. Outpatients
  8. Capable of providing written consent before participation in this study.

Exclusion Criteria:

  1. Grade III essential hypertension (i.e., sitting systolic blood pressure 180 mmHg or sitting diastolic blood pressure ≥ 110 mmHg), secondary hypertension, or malignant hypertension.
  2. Grade II essential hypertension (i.e., sitting systolic blood pressure ≥ 160 mmHg or sitting diastolic blood pressure ≥ 100 mmHg) for which antihypertensive drug(s) are used
  3. Use of oral antihypertensive medication within 2 weeks before the start of the treatment period Participants who are on any antihypertensive agent at the time of informed consent can be enrolled in the study only after 2-week washout following informed consent.
  4. Use of RAS inhibitors or thiazolidines within 3 months before the start of the treatment period
  5. Type 1 diabetes mellitus
  6. Fasting blood glucose of < 180 mg/dL and HOMA-R of ≤ 1.6 at the start of the treatment period (Week 0)
  7. Receiving or requiring any of the following at the time of informed consent:

    • Insulin, glucagon-like peptide-1 (GLP-1) receptor agonists, or other parenteral hypoglycemic agents
    • Combination therapy with 3 or more oral hypoglycemic agents
  8. Change of antidiabetic medication (including dosage change) within 3 months before the start of the treatment period
  9. Having diagnosed/treated any of the following cardiovascular diseases within 3 months before the start of the treatment period:

    • Cardiac disease/condition: myocardial infarction, coronary revascularization procedure
    • Cerebrovascular disease: cerebral infarction, cerebral haemorrhage, transient ischaemic attack
    • Advanced hypertensive retinopathy (retinal bleeding or oozing, papilloedema)
  10. Having diagnosed/treated for any of the following cardiovascular diseases more than 3 months before the start of the treatment period, and is now still in unstable condition.

    • Cardiac disease/condition: myocardial infarction, coronary revascularization procedure
    • Cerebrovascular disease: cerebral infarction, cerebral haemorrhage, transient ischaemic attack
  11. Past or current history of any of the following cardiovascular diseases.

    • Cardiac valve stenosis
    • Angina pectoris requiring medication
    • Congestive cardiac failure requiring medication
    • Arrhythmia requiring medication (e.g., paroxysmal atrial fibrillation, severe bradycardia, torsade de pointes, and ventricular fibrillation)
    • Arteriosclerosis obliterans with intermittent claudication or other symptoms
  12. Have severe ketosis, diabetic coma or precoma, severe infection, or serious trauma
  13. Clinically evident renal disorder (e.g., eGFR <30 mL/min/1.73 m2)
  14. Markedly low bile secretion or severe hepatic disorder
  15. History of hypersensitivity or allergy to azilsartan or telmisartan or to both.
  16. Presence of hyperkalemia (potassium level ≥ 5.5 mEq/L on laboratory testing)
  17. Currently participating in any other clinical study.
  18. Pregnant women, women with possible pregnancy, or breast-feeding women.
  19. Other participants who are inappropriate for participation in this study in the opinion of the principal investigator or investigator.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02079805


Locations
Japan
Kyoto-Shi, Kyoto, Japan
Sponsors and Collaborators
Takeda
Investigators
Study Director: General Manager Takeda
  More Information

Responsible Party: Takeda
ClinicalTrials.gov Identifier: NCT02079805     History of Changes
Other Study ID Numbers: 279/NRP-001
U1111-1151-7168 ( Registry Identifier: UTN (WHO) )
AZI-P4-004 ( Other Identifier: Takeda )
JapicCTI-142461 ( Registry Identifier: JapicCTI )
First Submitted: March 4, 2014
First Posted: March 6, 2014
Results First Submitted: April 24, 2017
Results First Posted: August 2, 2017
Last Update Posted: August 2, 2017
Last Verified: April 2017

Additional relevant MeSH terms:
Diabetes Mellitus
Hypertension
Diabetes Mellitus, Type 2
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Vascular Diseases
Cardiovascular Diseases
Hyperinsulinism
Telmisartan
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action